HGH vs HGH Fragment 176-191
FDA Approved vs Moderate Research
monitor Researched · 90% Redundant lipolytic mechanism. Full HGH already contains the 176-191 sequence, so combining provides diminishing returns for fat loss while adding HGH-related side effects.
Molecular Data
HGH HGH Fragment 176-191
Weight 22,124 Da 1,817.1 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) 15-20 minutes
Chain 191 amino acids 16 amino acids
Type Single-chain polypeptide with two disulfide bridges hGH C-terminal fragment (176-191)
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Research Evidence
HGH HGH Fragment 176-191
Status FDA Approved Moderate Research
References 4 studies 4 studies
Latest 2024 2014
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.